ClinicalTrials.gov
public full text
Public Domain
GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study
GSK1349572 is an integrase inhibitor that is currently being evaluated for the treatment of HIV infection. The primary objective of this study is to determine whether the addition of a proton pump inhibitor, omeprazole, to GSK1349572 impacts the blood levels of GSK1349572. It will also evaluate if a high fat meal impacts the blood levels of GSK1349572. In addition, the safety, tolerability, and pharmacokinetics of single supratherapeutic (high) dose of GSK1349572 will be evaluated.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283#901234
- Study of GSK1363089 in Metastatic Gastric Cancer#1163799
- GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and Atazanavir#906309
- GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients#1096776
- Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer#1151045
Record · ID 900964
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive